1. Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight Heparins

   • Hesham S. Al-Sallami
   • Michael A. Barras
   • Stephen B. Duffull

   Current Opinion 18 December 2012 Pages: 567 - 571

   

2. Dipeptidylpeptidase-4 Inhibitors (Gliptins)

   • André J. Scheen

   Review Article 18 December 2012 Pages: 573 - 588

   

3. Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model

   • Gezim Lahu
   • Andreas Hünnemeyer
   • Axel Facius

   Original Research Article 18 December 2012 Pages: 589 - 606

4. Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

   • Angelika Weil
   • Paul Martin
   • Karl-Heinz Molz

   Original Research Article 18 December 2012 Pages: 607 - 618

   

5. Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans

   • Zvi Teitelbaum
   • Thierry Lave
   • Adam F. Cohen

   Original Research Article 18 December 2012 Pages: 619 - 632